These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8976869)

  • 1. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
    Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
    J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
    Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
    Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance].
    Zhang J; Liu H; Li S; Gu C
    Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.
    Eymin B; Gazzeri S; Brambilla C; Brambilla E
    Oncogene; 2002 Apr; 21(17):2750-61. PubMed ID: 11965548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
    Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
    J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
    Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
    Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
    Mol Med; 2000 Mar; 6(3):208-37. PubMed ID: 10965496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal expression of MDM-2 in breast carcinomas.
    Bueso-Ramos CE; Manshouri T; Haidar MA; Yang Y; McCown P; Ordonez N; Glassman A; Sneige N; Albitar M
    Breast Cancer Res Treat; 1996; 37(2):179-88. PubMed ID: 8750585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases.
    Emanuels AG; Koudstaal J; Burger MP; Hollema H
    Br J Cancer; 1999 Apr; 80(1-2):38-43. PubMed ID: 10389975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
    Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
    J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2/p53 co-expression in oral premalignant and malignant lesions: potential prognostic implications.
    Agarwal S; Mathur M; Srivastava A; Ralhan R
    Oral Oncol; 1999 Mar; 35(2):209-16. PubMed ID: 10435158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
    Gorgoulis VG; Zacharatos PV; Manolis E; Ikonomopoulos JA; Damalas A; Lamprinopoulos C; Rassidakis GZ; Zoumpourlis V; Kotsinas A; Rassidakis AN; Halazonetis TD; Kittas C
    Br J Cancer; 1998; 77(3):374-84. PubMed ID: 9472631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases.
    He J; Zhou F; Shao K; Hang J; Wang H; Rayburn E; Xiao ZX; Lee SW; Xue Q; Feng XL; Shi SS; Zhang CY; Zhang S
    Lung Cancer; 2007 Apr; 56(1):51-8. PubMed ID: 17275947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and MDM2 in the development and progression of bladder cancer.
    Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
    Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
    Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P
    Anticancer Res; 1998; 18(3A):1689-95. PubMed ID: 9673391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.